246 related articles for article (PubMed ID: 20562906)
1. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.
Wang Y; Ngo VN; Marani M; Yang Y; Wright G; Staudt LM; Downward J
Oncogene; 2010 Aug; 29(33):4658-70. PubMed ID: 20562906
[TBL] [Abstract][Full Text] [Related]
2. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
3. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.
Stelniec-Klotz I; Legewie S; Tchernitsa O; Witzel F; Klinger B; Sers C; Herzel H; Blüthgen N; Schäfer R
Mol Syst Biol; 2012; 8():601. PubMed ID: 22864383
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin is a therapeutic target in colorectal cancer.
Wang L; Gala M; Yamamoto M; Pino MS; Kikuchi H; Shue DS; Shirasawa S; Austin TR; Lynch MP; Rueda BR; Zukerberg LR; Chung DC
Int J Cancer; 2014 May; 134(9):2041-50. PubMed ID: 24519534
[TBL] [Abstract][Full Text] [Related]
5. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
7. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
8. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
[TBL] [Abstract][Full Text] [Related]
9. KRAS and YAP1 converge to regulate EMT and tumor survival.
Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
[TBL] [Abstract][Full Text] [Related]
10. ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.
Liu D; Skomorovska Y; Song J; Bowler E; Harris R; Ravasz M; Bai S; Ayati M; Tamai K; Koyuturk M; Yuan X; Wang Z; Wang Y; Ewing RM
Cancer Biol Ther; 2019; 20(1):90-100. PubMed ID: 30148686
[No Abstract] [Full Text] [Related]
11. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
13. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
16. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
[TBL] [Abstract][Full Text] [Related]
19. RAS oncogenic signal upregulates EZH2 in pancreatic cancer.
Fujii S; Fukamachi K; Tsuda H; Ito K; Ito Y; Ochiai A
Biochem Biophys Res Commun; 2012 Jan; 417(3):1074-9. PubMed ID: 22222375
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium.
Keller JW; Franklin JL; Graves-Deal R; Friedman DB; Whitwell CW; Coffey RJ
J Cell Physiol; 2007 Mar; 210(3):740-9. PubMed ID: 17133351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]